Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699914 · ClinicalTrials.gov registry record
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 438
- Enrollment target
NCT06699914: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06699914 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 438 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699914 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 438 participants
- Enrollment target
Study Summary
A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first brolucizumab injection (index date) were identified during the index period and were recruited during the data collection/recruitment period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2023-12-01 |
What the finished NCT06699914 record still lists
NCT06699914 is an observational study that tracks outcomes without assigning an intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06699914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06699914 about?
NCT06699914 is a clinical study titled "A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)". A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection. Patients who had records of at least 12 months of visits after the first bro...
What is the current status of trial NCT06699914?
This trial is currently completed. The enrollment target is 438 participants. The study started on 2022-09-06. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT06699914?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI